PROMISE Substudy to Assess For Effective Dose of Radiation (PROMISE-SAFER) Specific Aim 3b

Inclusion Criteria: All patients who meet inclusion criteria and enroll in the parent
PROMISE study will be eligible to participate in PROMISE-SAFER.

1. New or worsening chest pain syndrome or equivalent symptoms suspicious for clinically
significant coronary artery disease

2. No prior evaluation for this episode of symptoms

3. Planned non-invasive testing for evaluation of possible coronary artery disease

4. Men age > 55 and women age ≥65 years

5. If age in men 45 - 54 or women 50 - 64 years, then must have increased probability of
CAD due to EITHER:

A. Diabetes Mellitus (DM) requiring medical treatment OR Peripheral Arterial Disease
(PAD) defined as documented >50% peripheral arterial stenosis treated medically or
invasively OR Cerebrovascular disease (stroke, documented > 50% carotid stenosis
treated medically or invasively)

OR

B. At least one of the following cardiovascular risk factors:

- Ongoing tobacco use

- Hypertension

- Abnormal ankle-brachial index defined as less than <0.9

- Dyslipidemia

6. Serum creatinine < 1.5 mg/dL within the past 90 days

7. Negative urine/serum pregnancy test for female subjects of child-bearing potential and
not breast-feeding

Exclusion Criteria:

1. Diagnosed or suspected acute coronary syndrome requiring hospitalization or urgent or
emergent testing; Elevated troponin or creatinine kinase-MB

2. Hemodynamically or clinically unstable condition (systolic blood pressure < 90 mmHg,
atrial or ventricular arrhythmias, or persistent resting chest pain felt to be
ischemic despite adequate therapy)

3. Known coronary artery disease with prior myocardial infarction, percutaneous coronary
intervention, coronary artery bypass grafting or any angiographic evidence of coronary
artery disease ≥50% lesion in a major epicardial vessel.

4. Any invasive coronary angiography or non-invasive anatomic or functional
cardiovascular test for detection of coronary artery disease, including coronary
computed tomographic angiography and exercise electrocardiogram, within the previous
twelve (12) months.

5. Known significant congenital, valvular (> moderate) or cardiomyopathic process
(hypertrophic cardiomyopathy or reduced systolic left ventricular function (left
ventricular ejection fraction ≤ 40%)) which could explain cardiac symptoms.

6. Contraindication to undergoing a coronary computed tomographic angiography, including
but not limited to:

a. Pregnancy or breastfeeding

7. Life expectancy < 2 years

8. Unable to provide written informed consent or participate in long-term follow-up